Parker Institute for Cancer Immunotherapy's John Connolly on what he is seeing at #SITC23
- blonca9
- Nov 4, 2023
- 1 min read
John Connolly describes trends he is seeing in cell therapy, bi-specific engagers, myeloid checkpoint targets, and combinations.